Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.

ABSTRACT:

Objective

Neonatal abstinence syndrome (NAS)--a clinical entity of infants from in utero exposure to psychoactive xenobiotic and buprenorphine--has been successfully used to treat NAS. However, nothing is known about the pharmacokinetics (PK) of buprenorphine in neonates with NAS. To our knowledge, this is the first study to investigate the population pharmacokinetic of sublingual buprenorphine in neonates with NAS.

Design

A retrospective population PK analysis of: (1) neonates with NAS treated with sublingual buprenorphine in randomized, double blinded clinical study and (2) data from healthy adults from a previously published pharmacokinetic study.

Setting

Neonatal intensive care unit and general clinical research unit.

Patients

Twenty-four neonates with NAS

SUBMITTER: Ng CM 

PROVIDER: S-EPMC5119858 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature